Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dinulescu

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Annales De Dermatologie Et De Venereologie|November 26, 2019
[Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices]C Orion, M Dinulescu, S Dalac-Rat, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2006
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerRafael Pieretti-Vanmarcke, Patricia K Donahoe, Lisa A Pearsall, et al.
Oncogene|December 5, 2003
c-CBL is not required for leukemia induction by Bcr-Abl in miceDaniela M Dinulescu, Lisa J Wood, Lei Shen, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2006
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessPaul P Szotek, Rafael Pieretti-Vanmarcke, Peter T Masiakos, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 10, 2009
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered miceIris L Romero, Ilyssa O Gordon, Sujatha Jagadeeswaran, et al.
Angewandte Chemie (International Ed. in English)|September 15, 2015
Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer CellsJie Li, Yi Kuang, Junfeng Shi, et al.
Oncotarget|September 8, 2016
Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stromaYuanyuan Hua, Pui-Wah Choi, Alexander J Trachtenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacyAbhimanyu S Paraskar, Shivani Soni, Kenneth T Chin, et al.
Cancer Research|October 15, 2013
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacyAshish A Kulkarni, Bhaskar Roy, Poornima S Rao, et al.
Annales De Dermatologie Et De Venereologie|August 3, 2025
Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patientsC David, C Coquelle, Y Le Corre, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Annales De Dermatologie Et De Venereologie|November 26, 2019
[Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices]C Orion, M Dinulescu, S Dalac-Rat, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2006
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancerRafael Pieretti-Vanmarcke, Patricia K Donahoe, Lisa A Pearsall, et al.
Oncogene|December 5, 2003
c-CBL is not required for leukemia induction by Bcr-Abl in miceDaniela M Dinulescu, Lisa J Wood, Lei Shen, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2006
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessPaul P Szotek, Rafael Pieretti-Vanmarcke, Peter T Masiakos, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 10, 2009
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered miceIris L Romero, Ilyssa O Gordon, Sujatha Jagadeeswaran, et al.
Angewandte Chemie (International Ed. in English)|September 15, 2015
Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer CellsJie Li, Yi Kuang, Junfeng Shi, et al.
Oncotarget|September 8, 2016
Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stromaYuanyuan Hua, Pui-Wah Choi, Alexander J Trachtenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacyAbhimanyu S Paraskar, Shivani Soni, Kenneth T Chin, et al.
Cancer Research|October 15, 2013
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacyAshish A Kulkarni, Bhaskar Roy, Poornima S Rao, et al.
Annales De Dermatologie Et De Venereologie|August 3, 2025
Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patientsC David, C Coquelle, Y Le Corre, et al.
Pageof 6